Mitochondria Based Therapeutics 3Q Investor Presentation November 6, 2019 WWW.COHBAR.COM NASDAQ: CWBR 1
Presentation information Investor Update and Slide Presentation: Date: November 6, 2019 Time: 5:00 p.m. (ET) 2:00 p.m. (PT) Conference Audio Dial-in U.S. and Canada: (877) 451-6152 Dial-in International: (201) 389-0879 Conference ID No.: 13694507 Slide Presentation Go to www.webex.com, click on the ‘Join’ button and enter meeting number 920 124 970 and Password CWBR, or Go to www.cohbar.com and click on Annual Shareholder Presentation at top of homepage An audio recording of the call will be available beginning at 8:00 p.m. (ET) on November 6, 2019, through November 27, 2019. To access the recording please dial 1-844-512-2921 in the U.S. and Canada, or 1-412-317-6671 internationally, and reference Conference ID No. 13694507. The audio recording along with the slide presentation will also be available at www.cohbar.com during the same period. 2
Forward Looking Statements This presentation includes forward-looking statements which are not historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and other future conditions. In some cases you can identify these statements by forward-looking words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “could,” “should,” “would,” “project,” “plan,” “expect,” “goal,” “seek,” “future,” “likely” or the negative or plural of these words or similar expressions. Examples of such forward-looking statements including but not limited to statements regarding anticipated outcomes of research and clinical trials for our lead candidate, CB4211, or other mitochondria based therapeutic (MBT) candidates; expectations regarding the future market for any drug we may develop; expectations regarding the growth of MBTs as a significant future class of drug products; statements regarding future partnership and collaboration opportunities; statements regarding anticipated therapeutic properties and potential of our MBTs or the properties, potential and effects of newly-discovered mitochondrial-derived peptides; statements regarding our capital resources and future financing plans, including our ability to successfully undertake financing activities; and expectations regarding our ability to effectively protect and expand our intellectual property. You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in these forward looking statements. Factors that could cause actual results to differ materially from these forward-looking statements include: our ability to successfully advance drug discovery and development programs, including the delay or termination of ongoing clinical trials; our possible inability to mitigate the prevalence and/or persistence of the injection site reactions, receipt of unfavorable feedback from regulators regarding the safety or tolerability of CB4211 or the possibility of other developments affecting the viability of CB4211 as a clinical candidate or its commercial potential; results that are different from earlier data results including less favorable than and that may not support further clinical development; our ability to raise additional capital when necessary to continue our operations; our ability to recruit and retain key management and scientific personnel; and our ability to establish and maintain partnerships with corporate and industry partners. Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission and applicable Canadian securities regulators, including the “Risk Factors” set forth in our Annual Report on Form 10-K, as supplemented by our quarterly reports on Form 10-Q. The forward-looking statements and other information contained in this presentation are made as of the date hereof and CohBar, Inc. does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. 3
Summary Financials Income Statement ($000s) 3Q 2019 3Q 2018 Research & Development $1,944 $3,436 General & Administrative 1,284 1,062 Net Loss (3,349) (4,613) Net Loss Per Share – Basic & Diluted (0.08) (0.11) Balance Sheet ($000s) 9/30/19 12/31/18 Cash & Investments $14,420 $22,183 Stockholders Equity 10,978 17,963 4
3Q Business Update • Overview • Research and Development • Mitochondrial Medicine • Strategic Perspective • Plan 2019 • Goals 2020 5
CohBar: Mitochondria Based Therapeutics designed to treat chronic CohBar: Mitochondria Based Therapeutics designed to treat chronic diseases and to increase healthy lifespan diseases and to increase healthy lifespan • • Mitochondria: Central role in energy production, signaling and regulation. Mitochondrial dysfunction plays an Mitochondria: Central role in energy production, signaling and regulation. Mitochondrial dysfunction plays an underlying role in a number of chronic and age-related diseases in large and orphan patient populations. underlying role in a number of chronic and age-related diseases in large and orphan patient populations. • • Platform Technology: Evaluation of over 100 peptides encoded in the mitochondrial DNA and their analogs for Platform Technology: Evaluation of over 100 peptides encoded in the mitochondrial DNA and their analogs for potential development into novel therapeutics potential development into novel therapeutics • • Clinical Stage: CB4211 in Phase 1a/1b trial for NASH and obesity. Phase 1a complete. Improvement in NAS Clinical Stage: CB4211 in Phase 1a/1b trial for NASH and obesity. Phase 1a complete. Improvement in NAS score, liver fat and triglyceride levels and body weight reduction shown in preclinical models as well as anti-fibrotic score, liver fat and triglyceride levels and body weight reduction shown in preclinical models as well as anti-fibrotic effects effects • • Preclinical Stage: New peptides have wide range of effects in models. Anti-fibrotic effects in IPF, enhanced killing Preclinical Stage: New peptides have wide range of effects in models. Anti-fibrotic effects in IPF, enhanced killing of cancer cells by human blood cells in vitro , improved glucose tolerance in Type 2 diabetes of cancer cells by human blood cells in vitro , improved glucose tolerance in Type 2 diabetes • • Potential Indications: NASH, obesity, cancer, fibrotic diseases and type 2 diabetes Potential Indications: NASH, obesity, cancer, fibrotic diseases and type 2 diabetes • • IP: 65+ CohBar patent filings, 8 issued patents licensed from UCLA/Albert Einstein/Mayo Clinic IP: 65+ CohBar patent filings, 8 issued patents licensed from UCLA/Albert Einstein/Mayo Clinic • • Experienced Team: Successful track record of drug discovery, development and partnerships Experienced Team: Successful track record of drug discovery, development and partnerships • • Financial: $14.4M 3Q 2019, runway expected into 4Q 2020 Financial: $14.4M 3Q 2019, runway expected into 4Q 2020 6 6
CB4211 Clinical Program 7
CB4211: Lead candidate in Phase 1a/1b trial for NASH and Obesity • Phase 1a stage completed: No safety issues observed under the amended protocol o Phase 1a design: SAD/MAD safety, tolerability and PK in healthy subjects o First mitochondria based therapeutic in humans • Phase 1b stage patient recruitment ongoing: Activity readout currently anticipated mid-2020 o Phase 1b design: Measuring changes in liver fat, body weight, and biomarkers in 20 obese NAFLD subjects, 10 active/10 placebo, 4 week exposure • Preclinical evidence of efficacy in animal models of NASH and obesity o NASH: reduced NAFLD Activity Score ; Obesity: reduced body weight/fat mass, liver fat o Novel Mechanism of Action: Enhances insulin effects on fat cells (adipocytes) leading to reduction of liver fat o Synergistic effects with other mechanisms used in diabetes and obesity: GLP-1 and PPARy agonists, potential for combination with other NASH or diabetes drugs 8
CB4211: Efficacy in Animal Models of NASH and Obesity (Review) Reduced NAS Score in STAM Mice Reduced Body Weight in DIO Mice Reduced Liver Fat in DIO MIce NAS Score at Day 21 Body Weight Change at Day 21 Fat Mass and Liver Histology at Day 21 0 - 2 0 L o s s ( g ) C h a n g e i n B W ( % ) - 4 - 5 L e a n M a s s - 6 F a t M a s s - 1 0 - 8 L i r a g l u t i d e C B 4 2 0 9 - 1 5 * * * - 2 0 Vehicle CB4209 CB4211 I P I P C Vehicle Control Liraglutide CB4209 Fewer Fat Deposits STAM Mice NAS = steatosis + inflammation + ballooning 1 Source: Cundy KC, et al. AASLD Poster, 2017 9
Recommend
More recommend
